{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:14:06Z","timestamp":1789884846291,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD0545700"],"award-info":[{"award-number":["2025ZD0545700"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170206,82470213"],"award-info":[{"award-number":["82170206,82470213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470213"],"award-info":[{"award-number":["82470213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170206"],"award-info":[{"award-number":["82170206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502606"],"award-info":[{"award-number":["2022YFC2502606"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502600"],"award-info":[{"award-number":["2022YFC2502600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1101503"],"award-info":[{"award-number":["2021YFA1101503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.951","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:15:02Z","timestamp":1766189702000},"page":"609.e1-609.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance"],"prefix":"10.1016","volume":"32","author":[{"given":"Jiayu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengkai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2719-3805","authenticated-orcid":false,"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.12.951_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.951_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/BS9.0000000000000229","article-title":"Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know","volume":"7","author":"Zhao","year":"2025","journal-title":"Blood Sci"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.951_bib0003","doi-asserted-by":"crossref","first-page":"530","DOI":"10.21147\/j.issn.1000-9604.2024.05.06","article-title":"Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"36","author":"Wang","year":"2024","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.951_bib0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-019-0751-4","article-title":"Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT","volume":"12","author":"Piemontese","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.951_bib0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.951_bib0006","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.951_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100863","article-title":"Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia","volume":"50","author":"Patel","year":"2021","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.951_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.951_bib0009","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.12.951_bib0010","article-title":"Prophylactic versus preemptive donor lymphocyte infusion in refractory\/relapsed aml post-allogeneic transplant: a retrospective comparative study","author":"Wu","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"10.1016\/j.jtct.2025.12.951_bib0011","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.951_bib0012","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/S2352-3026(25)00172-3","article-title":"Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Robin","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.12.951_bib0013","article-title":"Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"9","author":"Kungwankiattichai","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtct.2025.12.951_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-136671","article-title":"Safety and efficacy of maintenance treatment following allogeneic hematopoietic cell transplant in acute myeloid leukemia and myelodysplastic syndrome - a systematic review and meta-analysis","volume":"136","author":"Bewersdorf","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.951_bib0015","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1080\/10428194.2018.1443334","article-title":"Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies","volume":"59","author":"Maples","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.951_bib0016","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.951_bib0017","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jtct.2025.12.951_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-024-00976-1","article-title":"MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study","volume":"14","author":"Cao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.951_bib0019","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1182\/blood.2024024010","article-title":"How I use maintenance therapy in acute myeloid leukemia","volume":"145","author":"Roboz","year":"2025","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jtct.2025.12.951_bib0020","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.951_bib0021","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.12.951_bib0022","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","article-title":"Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome","volume":"8","author":"Han","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"36","key":"10.1016\/j.jtct.2025.12.951_bib0023","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.951_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2025.101634","article-title":"Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions","volume":"38","author":"Fu","year":"2025","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.951_bib0025","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.951_bib0026","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.951_bib0027","first-page":"2289","article-title":"Maintenance therapy in acute myeloid leukemia: advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.jtct.2025.12.951_bib0028","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2025.12.951_bib0029","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.951_bib0030","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.951_bib0031","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.951_bib0032","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cytogfr.2006.05.002","article-title":"The role of G-CSF in adaptive immunity","volume":"17","author":"Franzke","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.951_bib0033","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1080\/10428194.2022.2070913","article-title":"Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis","volume":"63","author":"Hu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.951_bib0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-021-01157-8","article-title":"Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome","volume":"13","author":"Li","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.951_bib0035","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.jtct.2025.12.951_bib0036","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:09:10Z","timestamp":1780312150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725026132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636725026132"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.951","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}